Skip to main content
رجوع
TMDX logo

TransMedics Group, Inc.

جودة البيانات: 100%
ذروة بيع
TMDX
NASDAQ Healthcare Medical - Devices
KWD 108.92
▼ KWD 3.16 (-2.82%)
القيمة السوقية: 3.74B
نطاق اليوم
KWD 108.76 KWD 112.62
نطاق 52 أسبوعًا
KWD 62.23 KWD 156.00
حجم التداول
850,344
متوسط 50 يوم / 200 يوم
KWD 134.33 / KWD 125.91
الإغلاق السابق
KWD 112.08

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 19.6 0.3
P/B 7.9 2.9
ROE % 54.2 3.7
Net Margin % 31.4 3.8
Rev Growth 5Y % 111.5 10.0
D/E 1.0 0.2

السعر المستهدف للمحللين

Hold
KWD 148.170 +36.0%
Low: KWD 135.000 High: KWD 166.000
مكرر الربحية المستقبلي
45.5
ربحية السهم المستقبلية
KWD 2.461
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
740 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 5.810
KWD 5.707 – KWD 5.922
 1.2 B 1
FY2028 KWD 4.866
KWD 4.502 – KWD 5.464
 1 B 5
FY2027 KWD 3.671
KWD 3.323 – KWD 4.048
 880 M 8

النقاط الرئيسية

Revenue grew 111.50% annually over 5 years — strong growth
Earnings grew 436.58% over the past year
ROE of 54.24% indicates high profitability
Net margin of 31.43% shows strong profitability
Generating 133.59M in free cash flow
PEG of 0.05 suggests growth is underpriced

النمو

Revenue Growth (5Y)
111.50%
Revenue (1Y)37.13%
Earnings (1Y)436.58%
FCF Growth (3Y)N/A

الجودة

Return on Equity
54.24%
ROIC8.64%
Net Margin31.43%
Op. Margin17.93%

الأمان

Debt / Equity
0.99
Current Ratio7.14
Interest Coverage7.88

التقييم

P/E Ratio
19.63
P/B Ratio7.90
EV/EBITDA34.24
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 37.13% Revenue Growth (3Y) 58.30%
Earnings Growth (1Y) 436.58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 111.50% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 605.49M Net Income (TTM) 190.29M
ROE 54.24% ROA 17.81%
Gross Margin 59.92% Operating Margin 17.93%
Net Margin 31.43% Free Cash Flow (TTM) 133.59M
ROIC 8.64% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.99 Current Ratio 7.14
Interest Coverage 7.88 Dividend Yield 0.00%
Valuation
P/E Ratio 19.63 P/B Ratio 7.90
P/S Ratio 6.17 PEG Ratio 0.05
EV/EBITDA 34.24 Dividend Yield 0.00%
Market Cap 3.74B Enterprise Value 3.72B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 605.49M 441.54M 241.62M 93.46M 30.26M
Net Income 190.29M 35.46M -25.03M -36.23M -44.22M
EPS (Diluted) 4.87 1.01 -0.77 -1.23 -1.60
Gross Profit 362.81M 262.08M 154.09M 65.27M 21.16M
Operating Income 108.58M 37.50M -28.73M -31.44M -39.43M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.07B 804.08M 706.05M 277.15M 134.89M
Total Liabilities 595.27M 575.47M 568.85M 89.77M 67.04M
Shareholders' Equity 473.10M 228.60M 137.20M 187.38M 67.85M
Total Debt 469.69M 518.29M 515.95M 67.56M 43.80M
Cash & Equivalents 488.37M 336.65M 394.81M 201.18M 25.58M
Current Assets 637.78M 497.22M 510.65M 252.29M 118.71M
Current Liabilities 89.31M 59.91M 54.93M 23.66M 23.24M

درجات الاستراتيجيات

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Growth Investing (Philip Fisher)
#16 of 157
88
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#26 of 332
77
Custom Full Throttle
#77 of 146
45
Custom Lower Risk
#33 of 140
54

النشاط الأخير

دخل Growth Investing (Philip Fisher)
Mar 24, 2026
دخل Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
دخل Full Throttle
Mar 24, 2026
دخل Lower Risk
Mar 24, 2026